Trials / Recruiting
RecruitingNCT06826313
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Detailed description
To evaluate VRT106 for injection in patients with locally advanced/metastatic solid tumours for safety and tolerability, exploring the maximum tolerated dose (MTD)/maximum administered dose (MAD)/optimal bioavailable dose (OBD) and/or the recommended phase II clinical dose (RP2D) to provide a recommended dose for subsequent clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VRT106 | Intravenous drip administration |
Timeline
- Start date
- 2025-03-19
- Primary completion
- 2025-12-30
- Completion
- 2027-03-01
- First posted
- 2025-02-13
- Last updated
- 2025-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06826313. Inclusion in this directory is not an endorsement.